Table I.
Samples description
| n = 560 | Site* | Platform | Mean age |
Gender** | Stage** | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| right | left | rectum | male | female | I | II | III | IV | |||
|
MECC-A
n = 123 |
55 (44.7%) |
57 (46.4%) |
11 (8.9%) |
Affy HG- U133A |
72.53 | 68 (55.3%) |
55 (44.7%) |
4 (3.4%) |
58 (50%) |
41 (35.4%) |
13 (11.2%) |
|
MECC-P2
n = 161 |
58 (36.9%) |
59 (37.6%) |
40 (25.5%) |
Affy U133 Plus 2.0 |
72.01 | 87 (54%) |
74 (46%) |
20 (15.4%) |
55 (42.3%) |
39 (30%) |
16 (12.3%) |
|
GSE14333
n = 215 |
79 (37.1%) |
100 (46.9%) |
34 (16%) |
Affy U133 Plus 2.0 |
65.65 | 132 (61.4%) |
83 (38.6%) |
34 (15.8%) |
61 (28.4%) |
64 (29.8%) |
56 (26%) |
|
GSE13294
n = 61 |
46 (75.4%) |
15 (24.6%) |
Affy U133 Plus 2.0 |
65.43 | 32 (53.3%) |
28 (46.7%) |
0 (0%) |
46 (75.4%) |
7 (11.5%) |
8 (13.1%) |
|
*
Some cases were classified as “colon” with no information about specific sub-site
**
Number may not add to total due to missing information